RMC-5552 Monotherapy in Adult Subjects With Recurrent Glioblastoma
A Phase I/Ib, Open-Label, Dose-Escalation Study of RMC-5552 Monotherapy in Adult Subjects With Recurrent Glioblastoma
Sponsor: National Cancer Institute (NCI)
Listed as NCT05557292, this PHASE1 trial focuses on Glioblastoma and Recurrent Glioblastoma and remains actively recruiting participants. Sponsored by National Cancer Institute (NCI), it has been updated 12 times since 2023, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
12 versions recorded-
Oct 2025 — Present [monthly]
Recruiting PHASE1
Status: Suspended → Recruiting
-
May 2025 — Oct 2025 [monthly]
Suspended PHASE1
Status: Recruiting → Suspended
-
Dec 2024 — May 2025 [monthly]
Recruiting PHASE1
-
Sep 2024 — Dec 2024 [monthly]
Recruiting PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1
▶ Show 7 earlier versions
-
May 2024 — Jul 2024 [monthly]
Recruiting PHASE1
Status: Active Not Recruiting → Recruiting
-
Nov 2023 — May 2024 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
May 2023 — Nov 2023 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Apr 2023 — May 2023 [monthly]
Not Yet Recruiting PHASE1
-
Mar 2023 — Apr 2023 [monthly]
Not Yet Recruiting PHASE1
-
Dec 2022 — Mar 2023 [monthly]
Not Yet Recruiting PHASE1
-
Sep 2022 — Dec 2022 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- National Cancer Institute (NCI)
- Nicholas Butowski
- Revolution Medicines, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .